PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma

Overview

Journal Cancer Res

Specialty Oncology

Date 2024 Feb 21

PMID 38382068

Authors

Guannan Shu

Minyu Chen

Wuyuan Liao

Liangmin Fu

Mingjie Lin

Chengpeng Gui

Junjie Cen

Jun Lu

Zhenhua Chen

Jinhuan Wei

Wei Chen

Yinghan Wang

Jiangquan Zhu

Tianxin Zhao

Xiaonan Liu

Jiajia Jing

Guo-Chang Liu

Yihui Pan

Junhang Luo

Jiaxing Zhang

Affiliations

Soon will be listed here.

Abstract

Significance: PABPC1L functions as a key factor in renal cell carcinoma immune evasion, enhancing IDO1 and impeding T-cell function, and represents a potential target to enhance the efficacy of immune checkpoint blockade therapy.

Citing Articles

Clinical and molecular prognostic nomograms for patients with papillary renal cell carcinoma.

Wang X Discov Oncol. 2024; 15(1):780.

PMID: 39692801 PMC: 11655765. DOI: 10.1007/s12672-024-01669-8.

Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.

Jia Y, Dong X, Yang F, Zhou L, Long H BMC Nephrol. 2024; 25(1):298.

PMID: 39256647 PMC: 11384682. DOI: 10.1186/s12882-024-03735-3.

Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma.

Wang S, Li Y, Lin Y, Li J, Guo L, Wang H Sci Rep. 2024; 14(1):11985.

PMID: 38796629 PMC: 11127953. DOI: 10.1038/s41598-024-62738-0.

References

Zhai L, Bell A, Ladomersky E, Lauing K, Bollu L, Nguyen B . Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021; 27(23):6514-6528. PMC: 8639612. DOI: 10.1158/1078-0432.CCR-21-1392. View

Metz R, Rust S, DuHadaway J, Mautino M, Munn D, Vahanian N . IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012; 1(9):1460-1468. PMC: 3525601. DOI: 10.4161/onci.21716. View

Cho Y, Kim M, Chung H, Hwang E . Novel immunotherapy in metastatic renal cell carcinoma. Investig Clin Urol. 2017; 58(4):220-227. PMC: 5494344. DOI: 10.4111/icu.2017.58.4.220. View

Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M . Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015; 3(9):1017-29. PMC: 4561186. DOI: 10.1158/2326-6066.CIR-14-0244. View

Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L . NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018; 19(10):1112-1125. DOI: 10.1038/s41590-018-0207-y. View

Guzeloglu-Kayisli O, Lalioti M, Babayev E, Torrealday S, Karakaya C, Seli E . Human embryonic poly(A)-binding protein (EPAB) alternative splicing is differentially regulated in human oocytes and embryos. Mol Hum Reprod. 2013; 20(1):59-65. DOI: 10.1093/molehr/gat061. View

Alissafi T, Hatzioannou A, Legaki A, Varveri A, Verginis P . Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. J Autoimmun. 2019; 104:102310. DOI: 10.1016/j.jaut.2019.102310. View

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

10.

Prendergast G . Cancer: Why tumours eat tryptophan. Nature. 2011; 478(7368):192-4. DOI: 10.1038/478192a. View

11.

Williamson S, Taneja K, Cheng L . Renal cell carcinoma staging: pitfalls, challenges, and updates. Histopathology. 2018; 74(1):18-30. DOI: 10.1111/his.13743. View

12.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

13.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

14.

Moyer B, Rojas I, Murray I, Lee S, Hazlett H, Perdew G . Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor. Toxicol Appl Pharmacol. 2017; 323:74-80. PMC: 5495139. DOI: 10.1016/j.taap.2017.03.012. View

15.

Motzer R, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K . Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(1):71-90. PMC: 10191161. DOI: 10.6004/jnccn.2022.0001. View

16.

Mellor A, Keskin D, Johnson T, Chandler P, Munn D . Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002; 168(8):3771-6. DOI: 10.4049/jimmunol.168.8.3771. View

17.

Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T . Tumor-Repopulating Cells Induce PD-1 Expression in CD8 T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018; 33(3):480-494.e7. DOI: 10.1016/j.ccell.2018.02.005. View

18.

Smith C, Young Chang M, Parker K, Beury D, DuHadaway J, Flick H . IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012; 2(8):722-35. PMC: 3677576. DOI: 10.1158/2159-8290.CD-12-0014. View

19.

Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L . Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2015; 17(1):95-103. PMC: 4684796. DOI: 10.1038/ni.3313. View

20.

Denkert C, Loibl S, Noske A, Roller M, Muller B, Komor M . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2009; 28(1):105-13. DOI: 10.1200/JCO.2009.23.7370. View